SCHEMBL14294709

SCHEMBL14294709

N[C@@H](Cc1ccccc1)C(=O)OCCN1C(=O)CCC(N2C(=O)c3ccccc3C2=O)C1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP1LC3B Q9GZQ8 3/20 0.42
MMP2 P08253 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 5/20 0.39
LMNA P02545 1/20 0.39
TYR P14679 1/20 0.38
DPP4 P27487 1/20 0.38
POLB P06746 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PKM P14618 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 2/20 0.36
MAPT P10636 1/20 0.36
CHRM2 P08172 1/20 0.36
OPRM1 P35372 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
IKZF3 Q9UKT9 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14294602 0.87 MAP1LC3B (0.42) MAP1LC3BSMN1; SMN2ALDH1A1LMNAPOLB
Phenylalanine SCHEMBL14142283 0.86 PKM (0.44) MAP1LC3BMMP2ALDH1A1DPP4POLB
SCHEMBL14294603 0.85 MAP1LC3B (0.41) MAP1LC3BSMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL22143892 0.83 DDB1 (0.45) MMP2TYRDPP4DDB1CRBN
SCHEMBL4929873 0.82 MAP1LC3B (0.43) MAP1LC3BSMN1; SMN2ALDH1A1LMNAPOLB
SCHEMBL19889401 0.82 MMP2 (0.36) MAP1LC3BMMP2ALDH1A1TYRDPP4
SCHEMBL21335728 0.82 MMP2 (0.36) MAP1LC3BMMP2ALDH1A1TYRDPP4
SCHEMBL18923301 0.81 MAP1LC3B (0.41) MAP1LC3BSMN1; SMN2ALDH1A1L3MBTL1KMT2A
SCHEMBL14294650 0.80 SCN9A (0.49) KMT2A
SCHEMBL4940380 0.80 MAP1LC3B (0.43) MAP1LC3BSMN1; SMN2ALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9669015-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2017-06-06 US disclosed
US-8637545-B2 Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors TIANJIN HEMAY BIO-TECH CO., LTD. (CN) 2014-01-28 US disclosed
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TIANJIN HEMAY PHARMACEUTICAL CO., LTD. (CN) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051432-A1 PIPERIDINE-2, 6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS TNF, TNFRSF1A, TNFRSF9 MAP1LC3B 4651/4885MMP2 2733/4885SMN1; SMN2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.